亨迪药业：获得盐酸甲氧氯普胺化学原料药上市申请获批

Core Viewpoint - Hendi Pharmaceutical has received approval from the National Medical Products Administration for the marketing application of Methoclopramide Hydrochloride, a dopamine receptor antagonist used to alleviate nausea and vomiting symptoms, as well as to promote gastrointestinal motility to improve dyspepsia and delayed gastric emptying [1] Company Summary - Hendi Pharmaceutical (301211) announced the receipt of the approval notice for Methoclopramide Hydrochloride from the National Medical Products Administration [1] - The drug is primarily indicated for the relief of nausea and vomiting [1] - Additionally, it can aid in enhancing gastrointestinal motility, addressing issues such as dyspepsia and delayed gastric emptying [1]